Compare
Quest Diagnostics Inc vs Labcorp Holdings Inc. vs Fortrea Holdings Inc. vs RadNet, Inc.
| Latest fiscal year | Quest Diagnostics Inc DGX | Labcorp Holdings Inc. LH | Fortrea Holdings Inc. FTRE | RadNet, Inc. RDNT |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $11.04B | $13.95B | $2.72B | $2.04B |
| Revenue growth (YoY) | +11.8% | +7.2% | +1.0% | +11.5% |
| Gross margin | 33.2% (computed) | 28.8% | n/a | n/a |
| Operating margin | 14.1% | 9.9% | -32.0% | 3.0% |
| Net margin | 9.0% | 6.3% | -36.2% | -0.9% |
| Net income | $992.00M | $876.50M | -$986.20M | -$18.65M |
| EPS (Diluted) | $8.75 | $10.46 | -$10.81 | -$0.25 |
| Operating cash flow | $1.89B | $1.64B | $113.50M | $298.82M |
| Free cash flow | $1.36B | $1.21B | $88.30M | n/a |
| Cash & equivalents | $420.00M | $532.30M | $174.60M | $767.22M |
| Total assets | $16.23B | $18.39B | $2.72B | $3.76B |
| Total liabilities | n/a | $9.76B | $2.15B | $2.40B |
| Shareholders' equity | $7.21B | $8.62B | $563.50M | $1.36B |
| Return on year-end equity | 13.8% | 10.2% | -175.0% | -1.4% |
| Shares outstanding | n/a | 82.20M | 93.10M | 74.04M |
Revenue, most recent five fiscal years
| Fiscal year | Quest Diagnostics Inc | Labcorp Holdings Inc. | Fortrea Holdings Inc. | RadNet, Inc. |
|---|---|---|---|---|
| Latest | $11.04B Ended 2025-12-31 | $13.95B Ended 2025-12-31 | $2.72B Ended 2025-12-31 | $2.04B Ended 2025-12-31 |
| 1 year earlier | $9.87B Ended 2024-12-31 | $13.01B Ended 2024-12-31 | $2.70B Ended 2024-12-31 | $1.83B Ended 2024-12-31 |
| 2 years earlier | $9.25B Ended 2023-12-31 | $12.16B Ended 2023-12-31 | $2.84B Ended 2023-12-31 | $1.62B Ended 2023-12-31 |
| 3 years earlier | $9.88B Ended 2022-12-31 | $11.86B Ended 2022-12-31 | $2.84B Ended 2022-12-31 | $1.43B Ended 2022-12-31 |
| 4 years earlier | $10.79B Ended 2021-12-31 | $13.14B Ended 2021-12-31 | $3.06B Ended 2021-12-31 | $1.32B Ended 2021-12-31 |